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Exome Sequencing for Kidney Disease T argeted capture and sequencing of the protein-coding regions of the genome through exome sequencing is increasingly applied as a first-line diagnostic tool in clinical medicine, particularly for the diagnosis of metabolic and neurodevelopmental disorders in children, 1, 2 as well as for the detection of causal mutations in cancer. [3] [4] [5] In those contexts, exome sequencing can inform medical management, including the choice of therapy. 1, [6] [7] [8] [9] However, the usefulness of this approach has not been systematically studied for most constitutional disorders in adults. Because the diagnostic yield of exome sequencing can vary according to the clinical disorder and the population studied, 9 thorough investigations across different constitutional disorders are needed to inform its use in clinical practice.
Chronic kidney disease affects more than 10% of people worldwide, with substantial associated morbidity and mortality and a high burden in health care spending. 10 Yet the underlying mechanisms remain incompletely understood, and few targeted therapies are available. 10, 11 Approximately 25% of patients with chronic kidney disease report a family history, 12, 13 and mendelian causes are estimated to account for approximately 10% of cases of adult end-stage renal disease 14 and are a leading cause of nephropathy in children. 15 Chronic kidney diseases with mendelian causes often differ considerably from acquired forms of disease in their clinical prognosis, course, and indicated management, 11, 16 but they can be difficult to detect with the use of traditional diagnostics alone. 17, 18 Moreover, because chronic kidney disease of stage 1, 2, or 3 can be asymptomatic, the condition can go undetected until the patient has advanced-stage disease (stage 4 or 5; the stages of chronic kidney disease are described in Table S1 in Supplementary Appendix 1, available with the full text of this article at NEJM.org), at which point traditional diagnostic approaches such as renal biopsy may be either unrevealing or contraindicated altogether. Thus, in more than 10% of adult cases of newly diagnosed end-stage renal disease, the clinical diagnosis is said to be "other" or "unknown." [19] [20] [21] Such diagnostic ambiguity impedes clinical management, including tailored therapeutic interventions.
A number of smaller studies support the usefulness of exome sequencing for the diagnosis of early-onset or familial nephropathy [22] [23] [24] ; whether those findings can be extended to the broader patient population, which largely consists of adults with sporadic cases, is unclear. [19] [20] [21] To address this question, we conducted exome sequencing in two independent cohorts of patients with chronic kidney disease, totaling 3315 patients with conditions representing the broad clinical subcategories of nephropathy.
Me thods

Study Population
We performed proband-only exome sequencing in 3315 patients -1128 patients from A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA), a clinical trial involving 2773 patients with endstage renal disease who were 50 to 80 years of age and were recruited from 280 medical centers in 25 nations, 25 and 2187 patients from the Columbia University Medical Center (CUMC) Genetic Studies of Chronic Kidney Disease, a genetic research and biobanking study recruiting patients who are seen by the CUMC Nephrology Division for the evaluation and management of nephropathy (Section S1 and Tables S2, S3 , and S4 in Supplementary Appendix 1). The clinical diagnosis was classified according to broad etiologic category. For patients in the AURORA cohort, only these broad categories and diagnostic codes for their major clinical features were available; for patients in the CUMC cohort, more detailed clinical information was available from patients' electronic health records.
All the patients or their guardians provided written informed consent. The study was approved by the Columbia University Institutional Review Board and local ethics committees and was performed in accordance with the policy on bioethics and human biologic samples of the AURORA sponsor, AstraZeneca. The authors vouch for the accuracy and completeness of the data presented in this report.
Exome Sequencing and Variant Analysis
Genomic DNA was isolated from samples obtained from patients in accordance with standard protocols, captured with the use of the Roche or Integrated DNA Technologies (IDT) kit, T h e ne w e ngl a nd jou r na l o f m e dicine sequenced on Illumina platforms, and analyzed with an in-house pipeline to identify diagnostic variants for patients' renal disease (see Section S1 in Supplementary Appendix 1). In brief, we prioritized variants that occurred in a manually curated list of 625 nephropathy-associated genes (Table S5 in Supplementary Appendix 1) and also evaluated those variants in other mendelian disease-associated genes. Diagnostic variants were defined as those that were classified as "pathogenic" or "likely pathogenic" according to the American College of Medical Genetics and Genomics (ACMG) guidelines for clinical sequence interpretation 26 and that were explicative of the patient's nephropathy.
In addition, we separately analyzed the CUMC patients' sequence data for pathogenic variants in the 59 genes that would be recommended by the ACMG for reporting as medically actionable secondary findings to patients undergoing genomic sequencing. 27 This analysis was not performed for patients in the AURORA cohort, because the trial protocol and consent did not permit analysis of these patients' data for secondary findings. In accordance with the AURORA and CUMC consent protocols (see Section S1 in Supplementary Appendix 1) and with New York State regulations regarding research-level genome sequencing, the genetic results analyzed in this study were not returned directly to the participants in either cohort. The variants listed in Tables S6, S7 , S14, and S17 in Supplementary Appendix 2, available at NEJM.org, have been submitted to the National Center for Biotechnology Information ClinVar database (accession numbers, SCV000809114-SCV000809473 and SCV000853312-SCV000854401).
Statistical Analysis
Diagnostic yield was calculated on the basis of counts of variants classified as "pathogenic" or "likely pathogenic." We assessed the yield for each clinical diagnostic category using a logisticregression model (R function GLM), with diabetic nephropathy (for which the yield was lowest) used as the reference. In addition, we ran models with adjustment for cohort, sex, age at the time of study entry, self-identified non-European ancestry, and, for patients in the CUMC cohort, for whom data on family history were available, a family history of kidney disease. Pairwise comparisons were performed with a two-tailed Fisher's exact test. A Bonferroni-corrected P value of less than 0.007 was considered to indicate statistical significance.
R esult s
Cohort Characteristics
The characteristics of the 3315 patients who underwent sequencing are shown in Table 1 . The cohort was predominantly adult (3037 patients [91.6%] were >21 years of age), and 1179 patients (35.6%) reported having non-European ancestry. The patients had conditions that represented all major categories of nephropathy, [19] [20] [21] including nephropathy of unknown origin (281 patients [8.5%] ). Altogether, 2144 patients (64.7%) -all 1128 patients in the AURORA cohort and 1016 of the patients (46.5%) in the CUMC cohort -had end-stage renal disease. Family history, which was available only for the 2187 patients in the CUMC cohort, was positive for kidney disease in 619 patients (28.3%), a proportion similar to that reported previously.
12,13
Genetic Findings and Diagnostic Yield
We detected diagnostic variants in 307 of the 3315 patients (9.3%), encompassing 66 distinct monogenic disorders (Table 2) . Of these patients, 206 (67%) had an autosomal dominant disease, 42 (14%) an autosomal recessive disease, and 54 (18%) an X-linked disease. The remaining 5 of these 307 patients (2%) had dual molecular diagnoses. The 343 diagnostic variants that were detected included 167 protein-truncating variants and 176 nontruncating variants; 202 variants (59%) had been previously reported as pathogenic, and 141 variants (41%) had not at the time of analysis. The majority of diagnostic variants (228 of 343 [66%]) were absent from population control databases. Details of the diagnostic genetic findings are provided in Tables S8 through  S10 and Fig. S1 in Supplementary Appendix 1 and Table S7 in Supplementary Appendix 2.
Of the 66 distinct monogenic disorders detected, 6 accounted for 198 (63%) of the 312 genetic diagnoses (Fig. 1A) : autosomal dominant polycystic kidney disease (ADPKD) due to mutations in PKD1 (75 patients) or PKD2 (22); glomerulopathy due to mutations in COL4A3 (27) , COL4A4 (21), or COL4A5 (44); and UMOD-associated tubulo-interstitial disease (9) . However, the majority of genetic disorders identified (39 of 66 [59%]) were unique to a single patient ( Panel A shows the most common diagnostic genetic findings. In total, 312 genetic diagnoses, representing 66 distinct monogenic disorders, were detected in 307 patients, with 5 patients (2%) harboring dual molecular diagnoses (Tables S8 through S10 in Supplementary  Appendix 1 and Table S7 in Supplementary Appendix 2). Of the 66 distinct monogenic disorders observed, 6 collectively accounted for 63% of the genetic diagnoses: autosomal dominant polycystic disease due to mutations in PKD1 (75 patients) or PKD2 (22); glomerulopathy due to mutations in COL4A3 (27) , COL4A4 (21), or COL4A5 (44); and UMOD-associated tubulointerstitial disease (9) . Percentages do not total 100 because of rounding. Panel B shows the clinical diagnostic spectrum of patients with diagnostic variants in these genes; the percentage of patients belonging to a given diagnostic category among all the patients found to have diagnostic variants in the gene is shown. Patients who had diagnostic findings for nephropathy associated with COL4A3, COL4A4, or COL4A5 or for UMODassociated tubulointerstitial disease had a broad spectrum of clinical diagnoses. The clinical diagnostic spectrum that was observed for the other 60 genes, which accounted for the remaining 37% of genetic diagnoses, is shown alongside for comparison. The categories of clinical diagnoses are congenital or cystic renal disease, glomerulopathy, diabetic nephropathy, hypertensive nephropathy, tubulointerstitial disease, and nephropathy of unknown origin.
Remaining 60 genes, 37%
PKD1, 24%
PKD2, 7%
COL4A3, (Table S12 in Supplementary Appendix 1). Altogether, a family history of kidney disease and a clinical diagnosis of congenital or cystic renal disease and nephropathy of unknown origin were independent predictors of having a genetic diagnosis (Table 3, and  Table S13 in Supplementary Appendix 1).
In an additional 30 persons (0.9%), we detected putatively diagnostic variants for renal disorders that were not explicative of the patient's known clinical phenotype (Table S14 in Supplementary Appendix 2). These cases involved dual genetic diagnoses that may contribute to a complex clinical presentation or represent potential phenotypic expansions or clinical misclassification of nephropathy, such as with the putatively pathogenic COL4A3 and COL4A4 variants detected in 7 patients in the AURORA cohort who were reported to have tubulointerstitial disease. These cases would require additional clinical follow-up to reconcile the genetic findings with the reported phenotype.
We found the APOL1 risk genotypes 28, 29 0.07 * Odds ratios in this column were adjusted for cohort (AURORA or CUMC). † Family history data were available only for patients in the CUMC cohort.
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Clinical Implications of Genetic Diagnoses in the CUMC Cohort
For the 167 patients in the CUMC cohort who had a genetic diagnosis, we used the more detailed clinical data available to assess the diagnostic utility of the genetic findings from exome sequencing and their potential implications for clinical management (Table 4 , and (Table 4, and Table S7 in Supplementary Appendix 2). Patients with nephropathy of unknown origin accounted for three of the five dual molecular diagnoses observed in the whole cohort, a finding consistent with previous observations that dual molecular diagnoses cause ambiguous and complex phenotypes (Table S10 in Supplementary Appendix 1). 30 In the remaining 45 patients (27%) with a genetic diagnosis, the genetic findings confirmed the clinical diagnoses, encompassing 12 different monogenic nephropathies, including ADPKD and nephropathy associated with COL4A3, COL4A4, or COL4A5. Nonetheless, for 34 of these patients (76%), the genotype-level knowledge would provide additional clinical insight, including estimation of the risk of nephropathy progression, guidance for family counseling and donor selection for transplantation, or both (Table 4, and  Table S7 in Supplementary Appendix 2).
For 88 of the 167 patients (53%), the genetic diagnosis could initiate referral and evaluation for previously unrecognized extrarenal features of the associated diseases, spanning 15 different medical specialties (Table S7 in Supplementary Appendix 2). For 84 patients (50%), the genetic diagnosis could inform therapy -for example, by disfavoring immunosuppression among patients who were found to have monogenic forms of focal segmental glomerulosclerosis, by prompting referral to clinical trials that were targeted to the genetic disorder identified, or by leading to the institution of tailored therapies, such as thiazide diuretics and a high citrate diet for patients with Dent's disease.
Other Clinically Relevant Findings
We detected pathogenic variants in 16 of the 59 ACMG actionable genes in 34 of the 2187 patients (1.6%) in the CUMC cohort, and review of the electronic health records of these patients revealed that 26 (76%) had a personal or family history of clinical features consistent with the associated disorder (Table S17 in Supplementary Appendix 2). These secondary findings would lead to targeted subspecialty referral and workup, such as oncologic evaluation and mammography for patients with BRCA2 mutations detected. For each patient, these secondary genetic findings also had implications for nephrologic care, such as informing the use of immunosuppression in patients with findings for hereditary cancers or influencing dialysis or diuretic prescriptions for patients who were found to have a genetic predisposition to cardiac arrhythmias.
Discussion
In the present exome-sequencing study involving a diverse, largely adult combined cohort of 3315 patients with chronic kidney disease, we detected diagnostic variants in 307 patients (9.3%). This yield is similar to that observed for cancer, for which genomic diagnostics are routinely used. [3] [4] [5] We identified 66 distinct monogenic disorders, with a high rate of singleton genetic diagnoses and, among the patients with a particular genetic diagnosis, a range of clinical diagnoses. Moreover, we noted diagnostic variants in 48 of the 281 patients (17.1%) with nephropathy of unknown origin, a population that may comprise up to 15% of patients with newly diagnosed end-stage renal disease [19] [20] [21] and for whom traditional diagnostic methods are often unrevealing or contraindicated.
Overall, these findings emphasize the high degree of genetic and phenotypic heterogeneity of hereditary nephropathies and show the extent to which genetic testing can help to resolve clinical diagnostic challenges. In the CUMC cohort, for 57 of the 167 cases (34%) reviewed, the genetic findings reclassified disease or provided a cause for undiagnosed nephropathy, emphasizing the usefulness of the "agnostic" approach of exome sequencing, which assesses genes that otherwise may have gone unevaluated with the use of single-gene or phenotype-driven panel testing (Tables S18 and S19 in Supplementary Appendix 1). We also found that these more targeted approaches would constitute an effective first-line alternative for the patients who had relatively specific clinical presentations, such as ADPKD. Nonetheless, as indicated by the 3 patients who had clinical diagnoses of nephropathy of unknown origin and diagnostic PKD1 variants, broader genetic testing can help resolve atypical cases (Section S2 in Supplementary Appendix 1). Moreover, an analysis involving all 307 patients who had diagnostic variants found by exome sequencing revealed that applying a phenotype-specific panel would resolve, at most, 136 cases (44.3%) (Table S19 in Supplementary Appendix 1).
Detailed case-level review showed that for the majority of patients, the genetic diagnoses provided new clinical insight. Moreover, our results highlight the potential of genetic findings to alter medical management through initiating multidisciplinary care and, in some cases, also influencing the choice of therapy. For example, 56 of the 91 patients (62%) with COL4A3, COL4A4, or COL4A5 mutations did not have clinical diagnoses of the classically associated nephropathies (the Alport syndrome or thin basement membrane disease). For these patients, the genetic diagnosis would indicate ophthalmologic and otolaryngologic referral and, among the 15 patients (16%) with a clinical diagnosis of focal segmental glomerulosclerosis, would disfavor immunosuppressive therapy. Conversely, negative exome-sequencing results can also inform clinical management. For example, among patients with focal segmental glomerulosclerosis, the absence of genetic mutations in structural components of the glomerular basement membrane would indicate an acquired, immunologic cause of the condition and would support the use of immunosuppression. 31 We detected known or expected pathogenic variants in the 59 ACMG medically actionable genes in 34 of the 2187 patients (1.6%) assessed, a finding consistent with previous studies involving unselected adults. 32, 33 Although classically viewed as secondary findings, the findings for * Implications for clinical management included informing prognosis (e.g., regarding disease severity or transplantation), initiating referral for subspecialty care, and influencing the choice of therapy -for example, the use or avoidance of agents or referral of patients to clinical trials of therapies targeted to the underlying genetic disease. † A total of 20 genetic diagnoses were found multiple times, 16 of which were found among patients in different diagnostic utility categories. these genes had implications for nephrologic care in all cases. Conversely, the patients' nephropathy could also modify the management of these genetic diseases -for example, by influencing the choice of chemotherapeutic agents for patients with hereditary cancers. These results highlight what is both a key value and a challenge of genomewide assessment: one may detect genetic variants that are unrelated to the disorder under evaluation, which nonetheless can shape the management of the disorder. Because the majority of patients undergoing diagnostic genomic sequencing opt to receive findings in genes unrelated to the primary test indication, 34 our data reinforce the growing need for multidisciplinary collaborations to address such "secondary" findings.
Known limitations of exome sequencing include suboptimal coverage of some clinically relevant regions, such as the mitochondrial genome or the duplicated regions of PKD1. 35 The inability to detect intronic and copy-number variants represents an additional limitation. 36 Consequently, our study probably underestimates the overall burden of genetic disorders among patients with nephropathy. Beyond such technical limitations, our study illustrates the broader challenges of implementing exome sequencing among ethnically diverse adults, among whom biosamples from family members and antecedent health records are often unavailable. Familial testing can increase diagnostic yield relative to probandonly exome sequencing. 37 Moreover, as shown in 30 cases, putatively pathogenic variants were detected but either did not explain the patient's known renal phenotype or could not be fully adjudicated because of a lack of additional clinical information or supporting familial studies. Such variants may represent coexistent genetic diseases unrelated to the condition evaluated, new phenotypic expansions, or simple clinical misclassifications. We anticipate that their interpretation -and the resultant need for deeper phenotyping, including associated subspecialty referrals -will challenge geneticists and medical specialists.
The need to "reconsider disease ontology on the basis of molecular classifiers" to support precision medicine and augment clinical trials in nephrology has been highlighted in some publications. [38] [39] [40] Our findings support the diagnostic utility of exome sequencing across different clinical categories of kidney disease and highlight the potential of genetic testing to accurately direct patients to relevant clinical trials and targeted therapies, encouraging similar investigations across other subspecialties. We thank all the study participants for contributing to this effort, our colleagues in the Division of Nephrology and Department of Urology at Columbia University Medical Center, and the AURORA coinvestigators.
